HCRA Response On DRGs and Clinical Research Threat Called A “Stone Wall,” Legislative Remedy Sought
In Brief: Zubrod “One Person Who Made The Difference” In Drug Program, DeVita Says in Center’s 25th
AACI Told Medicare “Probably” Has Paid For Extra Patient Care Costs Of Research; Members Object To “Two Level System”
New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?









